|

货币单位:美元(USD)

Trillium Therapeutics ULC (tril)

实时(?):

盘后(?):

读取中...

-- (--%)

开盘价:--	最高价:--	最低价:--	52周最高价:--	52周最低价:--
成交量:--	平均成交量:--	市值:--	市盈率:--	预期市盈率:--
每股收益:--	贝塔系数:--	股息:--	收益率:--	总股本:--

提示:交易结束

Kathleen Large	Kathleen Large is a professional with experience in the pharmaceutical industry. She is currently the Senior Vice President-Clinical Operations at Trillium Therapeutics ULC since 2019. Previously, she worked as Vice President-Clinical Development at Histogenics Corp. and as Vice President-Development Operations at Aileron Therapeutics, Inc. from 2018 to 2019. Ms. Large completed her undergraduate degree at Boston College and her graduate degree at The University of California, San Francisco.
Deborah Baron	Deborah Baron is currently the Chief Executive Officer at Amplyx Pharmaceuticals, Inc. She also holds positions as the Director at Seagen Inc., the President & Director at Trillium Therapeutics ULC, and the Independent Director at Cerevel Therapeutics Holdings, Inc. Additionally, she is a Director at Cerevel Therapeutics, Inc. Previously, she worked as a Director at Global Blood Therapeutics, Inc. and as the Senior VP-Worldwide Business Development at Pfizer Inc. Ms. Baron completed her undergraduate degree at the Massachusetts Institute of Technology and holds an MBA from the MIT Sloan School of Management.

Kathleen Large

Kathleen Large is a professional with experience in the pharmaceutical industry. She is currently the Senior Vice President-Clinical Operations at Trillium Therapeutics ULC since 2019. Previously, she worked as Vice President-Clinical Development at Histogenics Corp. and as Vice President-Development Operations at Aileron Therapeutics, Inc. from 2018 to 2019. Ms. Large completed her undergraduate degree at Boston College and her graduate degree at The University of California, San Francisco.

Deborah Baron

Deborah Baron is currently the Chief Executive Officer at Amplyx Pharmaceuticals, Inc. She also holds positions as the Director at Seagen Inc., the President & Director at Trillium Therapeutics ULC, and the Independent Director at Cerevel Therapeutics Holdings, Inc. Additionally, she is a Director at Cerevel Therapeutics, Inc. Previously, she worked as a Director at Global Blood Therapeutics, Inc. and as the Senior VP-Worldwide Business Development at Pfizer Inc. Ms. Baron completed her undergraduate degree at the Massachusetts Institute of Technology and holds an MBA from the MIT Sloan School of Management.